Comparing the safety and efficacy of remimazolam and etomidate in elderly patients undergoing gastroscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071790

Enrollment

Unknown

Registered

2023-05-25

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopy

Interventions

RR Group:Remazolam combined with remifentanil for sedation

ER Group:Etomidate combined with remifentanil sedation

Eligibility

Sex/Gender

All

Age

65 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients who underwent painless gastroscopy in the outpatient department of our hospital from January 2023 to June 2023. 1. Age >= 65 years; 2. American Society of Anesthesiologists' (ASA) classification I-III; 3. Body Mass Index (BMI) 18-30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. High reflux aspiration; 2. Allergic to benzodiazepines or opioids; 3. History of drug abuse; 4. Take sedative, analgesic or antidepressant drugs within 24 hours; 5. Unable to cooperate with the communicator; 6. Liver and kidney dysfunction.

Design outcomes

Primary

Measure	Time frame
Blood pressure;Respiratory depression;	—

Secondary

Measure	Time frame
Recovery time;Discharge time;Nausea and vomiting;vertigo;	—

Countries

China

Contacts

Public ContactJun Li

Dazhou Central Hospital

346667814@qq.com+86 138 8288 8168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026